Goldman Sachs’s Myovant Sciences Ltd. MYOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,420,659
| Closed | -$65.3M | – | 6414 |
|
|
2022
Q4 | $65.3M | Buy |
2,420,659
+1,929,497
| +393% | +$50.8M | 0.02% | 964 |
|
|
2022
Q3 | $8.82M | Buy |
491,162
+72,826
| +17% | +$1.16M | ﹤0.01% | 2631 |
|
|
2022
Q2 | $5.2M | Buy |
418,336
+207,827
| +99% | +$2.29M | ﹤0.01% | 3091 |
|
|
2022
Q1 | $2.8M | Buy |
210,509
+21,019
| +11% | +$282K | ﹤0.01% | 3930 |
|
|
2021
Q4 | $2.95M | Buy |
189,490
+60,339
| +47% | +$1.15M | ﹤0.01% | 3905 |
|
|
2021
Q3 | $2.9M | Sell |
129,151
-49,594
| -28% | -$1.09M | ﹤0.01% | 3846 |
|
|
2021
Q2 | $4.07M | Sell |
178,745
-204,342
| -53% | -$4.3M | ﹤0.01% | 3529 |
|
|
2021
Q1 | $7.88M | Buy |
383,087
+249,313
| +186% | +$5.68M | ﹤0.01% | 2766 |
|
|
2020
Q4 | $3.69M | Sell |
133,774
-39,740
| -23% | -$774K | ﹤0.01% | 3247 |
|
|
2020
Q3 | $2.44M | Buy |
173,514
+88,576
| +104% | +$1.65M | ﹤0.01% | 3432 |
|
|
2020
Q2 | $1.75M | Buy |
84,938
+19,157
| +29% | +$261K | ﹤0.01% | 3554 |
|
|
2020
Q1 | $497K | Buy |
65,781
+13,265
| +25% | +$149K | ﹤0.01% | 4219 |
|
|
2019
Q4 | $815K | Buy |
52,516
+6,704
| +15% | +$67.6K | ﹤0.01% | 4237 |
|
|
2019
Q3 | $238K | Buy |
45,812
+26,967
| +143% | +$200K | ﹤0.01% | 4767 |
|
|
2019
Q2 | $171K | Buy |
+18,845
| New | +$281K | ﹤0.01% | 4836 |
|
|
2018
Q2 | – | Sell |
-9,444
| Closed | -$201K | – | 6128 |
|
|
2018
Q1 | $201K | Buy |
+9,444
| New | +$144K | ﹤0.01% | 5000 |
|
|
2017
Q3 | – | Sell |
-14,853
| Closed | -$174K | – | 6937 |
|
|
2017
Q2 | $174K | Buy |
+14,853
| New | +$184K | ﹤0.01% | 5869 |
|
|
2017
Q1 | – | Sell |
-464,635
| Closed | -$5.78M | – | 7076 |
|
|
2016
Q4 | $5.78M | Buy |
+464,635
| New | +$5.38M | ﹤0.01% | 2928 |
|
Other funds holding MYOV
Goldman Sachs's MYOV Position: Q1 2023 in Review
Goldman Sachs sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 2,420,659 shares — an estimated $65.3M sold.
Goldman Sachs first reported a position in MYOV in Q4 2016 and held it in 18 quarters. The position peaked at $65.3M in Q4 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.
- Goldman Sachs reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
- Goldman Sachs sold 2,420,659 Myovant Sciences Ltd. shares in Q1 2023, an estimated $65.3M.
- Goldman Sachs first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 18 quarters.
- Goldman Sachs's Myovant Sciences Ltd. position peaked at $65.3M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.
Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.